Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital, Ducane Road, London W12 0NN, UK.
Pediatr Rheumatol Online J. 2011 Jun 19;9:12. doi: 10.1186/1546-0096-9-12.
Primary systemic vasculitis presenting in childhood is an uncommon but serious condition. As these patients transfer to adult clinics for continuing care, defining long term outcomes with emphasis on disease and treatment- related morbidity and mortality is important. The aim of this study is to describe the long- term clinical course of paediatric patients with ANCA vasculitis.
The adult patients in our vasculitis clinics who had presented in childhood, with a follow up time of greater than 10 years were included. We also reviewed the literature for articles describing the clinical outcome of paediatric patients with ANCA vasculitis.
We describe the clinical course of 8 adults who presented in childhood with ANCA vasculitis. 7 patients had Wegener's granulomatosis and 1 had microscopic polyangiitis. The median age at presentation was 11.5 years, and follow up time ranged form 11 to 30 years. Induction therapy for all patients was steroids and/or cyclophosphamide. Maintenance therapy was with azathioprine or mycophenolate mofetil. Biological agents were used in 3 patients for relapsed disease in adulthood only.Seven patients achieved complete remission. All patients experienced disease relapse, with a median of 4 episodes. Kidney function was generally well preserved, with median eGFR 76 ml/min. Only one patient developed end-stage renal failure and one patient died after 25 years of disease. Treatment-related morbidity rates were high; 7 suffered from infections, 4 were infertile, 2 had skeletal complications, and 1 developed malignancy.
Close long- term follow up of paediatric patients with ANCA vasculitis is imperative, as this patient cohort is likely to live long enough to develop significant treatment and disease- related morbidities. Prospective cohort studies with novel therapies including paediatric patients are crucial to help us determine the best approach to managing this complex group of patients. In addition, although not yet observed in our series, late cardiovascular morbidity remains a major longer-term potential concern for adult survivors of paediatric vasculitis.
儿童期起病的原发性系统性血管炎是一种不常见但严重的疾病。随着这些患者转入成人诊所进行后续治疗,明确长期预后,重点关注疾病和治疗相关的发病率和死亡率非常重要。本研究旨在描述儿童期起病的抗中性粒细胞胞浆抗体(ANCA)血管炎患者的长期临床病程。
我们纳入了在我院血管炎门诊就诊的成年患者,这些患者在儿童期起病,随访时间超过 10 年。我们还查阅了文献中描述儿童期起病的 ANCA 血管炎患者临床结局的文章。
我们描述了 8 例在儿童期起病的 ANCA 血管炎成年患者的临床病程。7 例为韦格纳肉芽肿,1 例为显微镜下多血管炎。起病时的中位年龄为 11.5 岁,随访时间为 11 至 30 年。所有患者的诱导治疗均为激素和(或)环磷酰胺。维持治疗采用硫唑嘌呤或霉酚酸酯。仅 3 例患者在成年后疾病复发时使用生物制剂。7 例患者达到完全缓解。所有患者均经历疾病复发,中位复发次数为 4 次。肾功能总体良好,中位估算肾小球滤过率(eGFR)为 76ml/min。仅 1 例患者发展为终末期肾病,1 例患者在疾病发生 25 年后死亡。治疗相关发病率较高,7 例患者发生感染,4 例患者不孕,2 例患者发生骨骼并发症,1 例患者发生恶性肿瘤。
必须对儿童期起病的 ANCA 血管炎患者进行密切的长期随访,因为这群患者可能会存活足够长的时间,从而发生显著的治疗和疾病相关的并发症。包括儿童患者在内的新型治疗方法的前瞻性队列研究对于帮助我们确定管理这组复杂患者的最佳方法至关重要。此外,尽管在我们的系列中尚未观察到,但心血管疾病的迟发性发病仍然是儿童期血管炎成年幸存者的一个主要长期潜在问题。